VB Spine LLC (“VB Spine”) today announced that the U.S. Food and Drug Administration (FDA) granted two 510(k) clearances that expand the indications for its Vitoss® Bone Graft Substitute and interbody cage portfolio. The clearances allow Vitoss® to be used in the intervertebral disc space with interbody cages and expand the indications for VB Spine’s interbody cages to include use with bone void fillers cleared for use in intervertebral body fusion procedures, including Vitoss®.
Vitoss has long been used as a bone graft in the extremities, pelvis, and posterolateral spine. This new use in the anterior column of the spine includes interbody cages; additional indications include pediatric patients, and tumor-related cases, a combination not commonly cleared for synthetic bone grafts.
“This FDA clearance reflects the continued growth of our biologics portfolio and our commitment to broadening our offerings for surgeons and their patients,” said John Viscogliosi, co-CEO of VB Spine, speaking on behalf of his brothers and fellow co-CEOs Anthony and Marc Viscogliosi. “At VB Spine, everything starts with the patient, and giving surgeons more ways to treat their most complex cases is exactly the kind of growth we want to keep investing in.”
Surgeons treating anterior column defects have typically relied on autograft, bone harvested from elsewhere in the patient’s body, which can add operative time and discomfort at the donor site. The expanded indication gives surgeons an off-the-shelf option that avoids a second surgical site altogether.
This clearance is the latest addition to a biologics and technology portfolio that VB Spine has built over the past year, including its acquisitions of Augmedics’ xvision Spine System® and CT-Fluoro technology, as well as the launch of the Vulcan™ Spinal System. Together, they reflect VB Spine’s commitment to advancing spine care for the patients who need it most.
Read Also: Procode Raises $10M to Bring Its AI-powered Medical Billing Services to Every Surgical Specialty
